Orders agencies to secure "most-favored-nation" drug prices for Americans, mandating that US patients pay no more than the lowest price offered to developed nations globally, aiming to end perceived foreign "freeloading" on US drug costs. This EO compels price cuts by leveraging the US market, likely hitting pharma profits hard. Republicans may miss potential consumer relief; Democrats might overlook how this impacts innovation funding models reliant on high US prices or triggers complex trade disputes beyond simple "freeloading."